Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02576431 2025-11-12

NAVIGATE

Phase 2 Completed

215 enrolled 5 FDA

BreastDermatologicGastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Salivary Gland Neoplasms, Sarcoma, Thyroid Neoplasms, Colorectal Neoplasms

NCT03044587 2025-10-01

NIFE

Phase 2 Completed

93 enrolled

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma

NCT04466891 2025-09-15

HERIZON-BTC-01

Phase 2 Completed

87 enrolled 25 charts 3 FDA

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms

NCT03929666 2025-09-12

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Phase 2 Completed

74 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT00924027 2025-09-05

A Study of Patients Receiving High-Dose Rate Brachytherapy

Phase 2 Completed

43 enrolled 13 charts

GastrointestinalGenitourinaryGynecologic

Biliary Tract Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT03639935 2025-06-03

Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy

Phase 2 Completed

32 enrolled 14 charts

Gastrointestinal

Biliary Tract Neoplasms, Neoplasm Metastasis

NCT05239169 2025-05-01

Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

Phase 2 Completed

40 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT04907851 2025-03-17

KEYNOTE-E86

Phase 2 Completed

45 enrolled 25 charts

Gastrointestinal

Biliary Tract Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Phase 2 Completed

673 enrolled 22 charts

GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT04677504 2024-07-03

A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer

Phase 2 Completed

162 enrolled 18 charts

Gastrointestinal

Biliary Tract Neoplasms

NCT04720131 2024-01-30

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

Phase 2 Completed

28 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT03230318 2023-12-19

FIDES-01

Phase 2 Completed

148 enrolled 15 charts

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Liver Neoplasms, Cholangiocarcinoma

NCT03796429 2023-11-29

A Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in Advanced Biliary Tract Cancer

Phase 2 Completed

50 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT03260712 2023-11-03

Pembrolizumab in Biliary Tract Cancer

Phase 2 Completed

50 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Neoplasm Metastasis

NCT03833661 2023-10-25

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

Phase 2 Completed

159 enrolled 23 charts

Gastrointestinal

Biliary Tract Neoplasms, Camurati-Engelmann Syndrome, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04722133 2023-10-11

Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy

Phase 2 Completed

36 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT02866383 2023-09-22

CheckPAC

Phase 2 Completed

160 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Pancreatic Neoplasms

NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Phase 2 Completed

206 enrolled 40 charts 4 FDA

CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT05190575 2023-07-27

TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer

Phase 2 Completed

8 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT02821754 2023-03-28

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Phase 2 Completed

54 enrolled 14 charts

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Cholangiocarcinoma

NCT03079427 2022-12-06

Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma

Phase 2 Completed

101 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT03101566 2022-10-28

Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer

Phase 2 Completed

75 enrolled 14 charts

Gastrointestinal

Biliary Tract Neoplasms

NCT03524508 2022-08-24

Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer

Phase 2 Completed

178 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT03110328 2022-06-15

Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes

Phase 2 Completed

33 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT02703714 2022-01-25

Pembrolizumab and GM-CSF in Biliary Cancer

Phase 2 Completed

42 enrolled 19 charts

Gastrointestinal

Biliary Tract Neoplasms

NCT03111732 2021-12-03

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

Phase 2 Completed

11 enrolled 16 charts

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Liver Neoplasms, Cholangiocarcinoma

NCT03486678 2021-10-28

SHR-1210 in Combination With GEMOX in Patients With Advanced BTC

Phase 2 Completed

38 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT04656249 2021-06-04

LENABC

Phase 2 Completed

46 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT04642664 2021-06-03

ACABC

Phase 2 Completed

22 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT03778593 2021-02-04

FOLFIRINOX for 2nd-line Treatment of BTC

Phase 2 Completed

34 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT03830606 2021-02-01

The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma

Phase 2 Completed

54 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT03613168 2021-01-05

BILHER

Phase 2 Completed

4 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT02579616 2020-12-23

Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy

Phase 2 Completed

29 enrolled 16 charts

Gastrointestinal

Biliary Tract Neoplasms

NCT03231176 2020-11-19

Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer

Phase 2 Completed

62 enrolled

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms

NCT00948935 2020-03-11

Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma

Phase 2 Completed

35 enrolled 7 charts

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT02966821 2019-02-27

Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma

Phase 2 Completed

39 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT01917617 2019-02-21

Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer

Phase 2 Completed

50 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT02053376 2019-01-30

A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy

Phase 2 Completed

43 enrolled 15 charts

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT02433639 2018-09-10

Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer

Phase 2 Completed

24 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT01815307 2018-05-16

Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer

Phase 2 Completed

70 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT00142480 2018-04-25

Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer

Phase 2 Completed

8 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT02558959 2018-02-13

Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer

Phase 2 Completed

64 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT01943864 2017-05-31

A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers

Phase 2 Completed

20 enrolled 27 charts

Gastrointestinal

Biliary Tract Neoplasms, Neoplasms

NCT02346032 2017-04-26

Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma

Phase 2 Completed

4 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT00361231 2017-02-07

Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer

Phase 2 Completed

35 enrolled 6 charts

Gastrointestinal

Biliary Tract Neoplasms

Clinical Trials

Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer

Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

LEAP-005

NAVIGATE

NIFE

HERIZON-BTC-01

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

A Study of Patients Receiving High-Dose Rate Brachytherapy

Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy

Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

KEYNOTE-E86

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

FIDES-01

A Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in Advanced Biliary Tract Cancer

Pembrolizumab in Biliary Tract Cancer

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy

CheckPAC

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma

Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer

Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer

Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes

Pembrolizumab and GM-CSF in Biliary Cancer

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

SHR-1210 in Combination With GEMOX in Patients With Advanced BTC

LENABC

ACABC

FOLFIRINOX for 2nd-line Treatment of BTC

The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma

BILHER

Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy

Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer

Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma

Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma

Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer

A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy

Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer

Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer

Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer

Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer

A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers

Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma

Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer